Dicerna Pharma (DRNA) Misses Q2 EPS by 26c

Dicerna Pharma (NASDAQ: DRNA) reported Q2 EPS of ($0.68), $0.26 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c